GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » uniQure NV (NAS:QURE) » Definitions » Future 3-5Y EPS without NRI Growth Rate

QURE (uniQure NV) Future 3-5Y EPS without NRI Growth Rate : 13.37 (As of Mar. 31, 2025)


View and export this data going back to 2014. Start your Free Trial

What is uniQure NV Future 3-5Y EPS without NRI Growth Rate?

Future 3-5Y EPS without NRI Growth Rate is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

As of today, uniQure NV's Future 3-5Y EPS without NRI Growth Rate is 13.37.

Competitive Comparison of uniQure NV's Future 3-5Y EPS without NRI Growth Rate

For the Biotechnology subindustry, uniQure NV's Future 3-5Y EPS without NRI Growth Rate, along with its competitors' market caps and Future 3-5Y EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

uniQure NV's Future 3-5Y EPS without NRI Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, uniQure NV's Future 3-5Y EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where uniQure NV's Future 3-5Y EPS without NRI Growth Rate falls into.


;
;

uniQure NV  (NAS:QURE) Future 3-5Y EPS without NRI Growth Rate Explanation

Future 3-5Y EPS without NRI Growth Rate s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.

uniQure NV Future 3-5Y EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of uniQure NV's Future 3-5Y EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

uniQure NV Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » uniQure NV (NAS:QURE) » Definitions » Future 3-5Y EPS without NRI Growth Rate
Comparable Companies
ABUS CVAC GHRS ABCL AVBP LENZ DNTH PRTA TRVI FTRE VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
0EE0:UK UQ1:Germany
Address
Paasheuvelweg 25, Amsterdam, NH, NLD, 1105 BP
Website
https://www.uniqure.com
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.
Executives
Matthew C Kapusta director, officer: CEO, Managing Director 7358 MCVAY ROAD, GERMANTOWN TN 38138
Walid Abi-saab officer: Chief Medical Officer C/O UNIQURE N.V., PAASHEUVELWEG 25A, AMSTERDAM P7 11058BP
Jeannette Potts officer: See Remarks C/O FORMA THERAPEUTICS HOLDINGS, INC., 500 ARSENAL STREET, SUITE 100, WATERTOWN MA 02472
Christian Klemt officer: Chief Financial Officer PAASHEUVELWEG 25A, AMSTERDAM P7 1105 BP
Pierre Caloz officer: Chief Operating Officer UNIQURE N.V., PAASHEUVELWEG 25A, AMSTERDAM P7 P7 11058BP
Robert Gut director C/O VERSARTIS, INC., 4200 BOHANNON DRIVE, SUITE 250, MENLO PARK CA 94025
Leonard E Post director
Madhavan Balachandran director C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Jack Kaye director C/O KERYX BIOPHARMACEUTICALS, 750 LEXINGTON AVENUE, NEW YORK X1 10022
Rachelle Suzanne Jacques director C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 100 RIVER RIDGE DRIVE, NORWOOD MA 02062
David D. Meek director 3000 KENT AVENUE; SUITE A1-100, WEST LAFAYETTE IN 47906
Paula Soteropoulos director 49 WINONA STREET, PEABODY MA 01960
Jeremy P. Springhorn director C/O UNIQUIRE N.V., 113 HARTWELL AVENUE, LEXINGTON MA 02421
Ricardo Dolmetsch officer: President, R&D 113 HARTWELL AVENUE, LEXINGTON MA 02421
Kuta Alexander Edward Iii officer: Executive VP, Operations 239 WILLIS ROAD, SUDBURY MA 01776